Top Canadian researchers in charge of the pioneering Canadian proactive cohort study for people living with multiple sclerosis (CanProCo)


A team of world-leading MS researchers led by Dr. Jiwon Oh, selected to start working on the
first Canadian cohort to study the progression of multiple sclerosis

TORONTO, December 6, 2018 / CNW / – The Canadian Multiple Sclerosis Society and the Brain Canada Foundation today announced the team selected to lead the Canadian cohort to study the progression of multiple sclerosis (MS). Dr. Jiwon Oh, Based on County Dublin hotels The Hospital, and its team of nearly 50 MS researchers across disciplines across the country, were chosen to lead the $ 7 million Proactive Canadian Cohort Study for people living with MS (CanProCo). Financing partner Brain Canada receives financial support from Health Canada through the Canada Brain Research Fund. Biogen Canada is also a founding and funding partner of the project, providing support from the outset.

Dr. Oh, a neurologist and researcher, is conducting research on the development of advanced magnetic resonance imaging (MRI) techniques in MS. With an MD from Queen's University, followed by a PhD and a clinical fellowship in the Johns Hopkins Medical SchoolDr. Oh is dedicated to leading the charge against multiple sclerosis through his continuing research efforts. She helped create the North American Cooperative of Images in Multiple Sclerosis, which brings together academic centers that use magnetic resonance imaging for MS research.

"We are excited to have Dr. Jiwon Oh and his research team leads this unique project, which focuses on answering some of the perplexing issues surrounding MS, "said Dr. Pamela Valentine, president and CEO of MS Society of Canada. "As a leader in MS research, Dr. Oh has devoted her career to studying this disease and finding a cure." The team that is collaborating on this project brings a wealth of knowledge to the table with its expertise and support from our funding partners , Biogen and Brain Canada, this group has the potential to help the tens of thousands of Canadians living with multiple sclerosis. "

"Canada has one of the highest rates of multiple sclerosis in the world, so it's imperative that we learn more about this disease and how it progresses," said Dr. Oh. "By gaining a better understanding of the progression of MS, we can have a significant impact on how people manage their illness and improve the quality of life for many Canadians. "

CanProCo is the first project of its kind in Canada with the aim of gaining a better understanding of the unpredictable nature of disease progression. In addition to understanding why some people progress in their disease and others not, the researchers will also try to identify the triggers that lead to progression and establish methods to manage those triggers while also measuring the impact of MS on individuals as well as the Canadian health system . .

In addition to Dr. Oh, the team's top researchers include: Dr. Shannon Kolind (University of British Columbia), Dr. Larry Lynd (University of British Columbia), Dr. Scott Patten (University of Calgary), Dr. Alexandre Prat (CHUM Research Center), Dr. Roger Tam (University of British Columbia) and Dr. Anthony Traboulsee (University of British Columbia).

CanProCo will provide Dr. Oh and his team with the opportunity to collect and analyze data from Canadians living with multiple sclerosis, responding for biological, physical and socioeconomic factors, in an attempt to better understand the unique experiences of each individual with MS and obtain information on progression. Using data collected from the cohort, researchers hope to improve diagnosis, treatment and potentially prevent the onset of disease. The results of this study have the potential to impact how people live with MS and how we talk about the progression of MS in general.

Long-term monitoring of MS progression will help build a centralized, open data source that has the potential to help not only MS researchers but may also be relevant for researchers studying other neurodegenerative diseases including Alzheimer's, Parkinson's, Sclerosis Lateral Amyotrophic and Huntington. , due to the potential for common mechanisms of disease.

Recruitment for people living with MS to participate in this study will begin in early 2019. Click On here for more information on the Canadian MS Progression Cohort.

Background on the Canadian Proactive Cohort Study for People Living with MS (CanProCo)

Progression – a constant worsening of disease and increased disability – is a challenging reality faced by people affected by multiple sclerosis, and despite the great advances in multiple sclerosis research, the mechanism of progression and the ways in which researchers and clinicians can follow progression are not yet fully understood. CanProCo can have significant implications on how people living with MS manage and understand their disease from diagnoses and throughout the various stages of the disease. This study will analyze progression from the biological, physical and socioeconomic perspectives and will significantly involve people living with multiple sclerosis so that their individual experiences are captured. Ultimately, the cohort's goal is to connect biological findings with the real world and clinical findings to create a comprehensive picture of progression in multiple sclerosis, with the hope that researchers will better understand the unpredictable nature of multiple sclerosis and find a cure.

This $ 7 million investment in Canadian research is being generously supported by the founding partners. MS Society is grateful to lead donors, PCL Construction and Bennett Jones LLP for their generous support US $ 1.25 million and US $ 1 million, respectively, as well as for several individuals who made significant contributions.

About Multiple Sclerosis and the MS Society of Canada

Canada has one of the highest rates of multiple sclerosis in the world, with 11 Canadians diagnosed with multiple sclerosis every day. MS is a chronic, often disabling, disease of the central nervous system that comprises the brain, spinal cord and optic nerve. Most people with MS are diagnosed between the ages of 15 and 40 and the unpredictable effects of the disease last for the rest of their lives. The MS Society offers programs and services to people with multiple sclerosis and their families, advocates those living with multiple sclerosis and funds research to help improve the quality of life of people living with MS, and finally find a cure for MS. disease. Please visit or call 1-800-268-7582 to make a donation or for more information. Join the conversation and connect with the MS online community. Find the MS Society in Twitter, Instagram or enjoy our Facebook page.

About Brain Canada and the Canada Brain Research Fund

Brain Canada is a registered national charity based in Montreal, which enables and supports excellent, innovative and paradigm-changing brain research Canada. Since 1998, Brain Canada defended the brain as a unique and complex system with points in common across the gamut of neurological disorders, mental illnesses and addictions, brain and spinal cord injuries. Watching the brain as a system underscored the need for greater collaboration between disciplines and institutions and a smarter way to invest in brain research, focusing on outcomes that will benefit patients and families. Brain Canada's vision is to understand the brain, health and disease, to improve lives and achieve social impact.

The Canada Brain Research Fund is a public-private partnership between the Government of Brain Canada, designed to encourage Canadians to increase their support for brain research and maximize the impact and efficiency of these investments. Brain Canada Committed US $ 115 million of private donors and non-federal partners – now numbering more than 100 – with whom Health Canada joined US $ 120 million. For more information, visit or follow us at Twitter or Facebook.

SOURCE Canadian Multiple Sclerosis Society

For more information: Media Contacts: Jennifer Asselin, MS Society of Canada, 1-800-268-7582 ext. 3144, [email protected]; Michael Oliveira, St. Michael Hospital, 416-864-5047, [email protected]



Source link